Analysts Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Price Target at $16.56

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has earned an average rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and three have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $16.5556.

A number of equities research analysts have recently weighed in on the company. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently made changes to their positions in the company. Creative Planning bought a new stake in shares of Inventiva in the 2nd quarter valued at approximately $32,000. Commonwealth Equity Services LLC increased its holdings in shares of Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after acquiring an additional 12,704 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Inventiva in the 4th quarter valued at approximately $60,000. XTX Topco Ltd acquired a new position in Inventiva during the 4th quarter valued at approximately $84,000. Finally, NewEdge Advisors LLC acquired a new position in Inventiva during the 3rd quarter valued at approximately $116,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Stock Performance

IVA stock opened at $3.41 on Tuesday. Inventiva has a 52-week low of $2.85 and a 52-week high of $7.98. The stock’s 50 day moving average is $4.70 and its two-hundred day moving average is $5.34.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter. As a group, equities research analysts predict that Inventiva will post -0.79 EPS for the current fiscal year.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.